Alex Zwiers

Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom.

Part of PAION AG, Cenes Ltd. develops treatments for diseases of the central nervous system. The company is based in Histon, UK.

Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands.

Thuja Capital Management BV is a Venture Capital firm, a subsidiary of Thuja Capital Holding BV founded in 2006 by Harrold van Barlingen. Thuja Capital Management BV is headquartered in Utrecht.

Haemostatix Ltd. designs and develops solutions for haemostasis and thrombosis. Its products include Rapid and effective haemostatic action which is new class of topical coagulant or haemostat that is applied directly to a wound during surgery to control bleeding, and ready-to-use formulations, blood-free ingredients and a new class with a unique mode of action. The company was founded by Sarah Middleton and Alison Goodall in 2003 and is headquartered in Nottingham, the United Kingdom.

Janssen Pharmaceutica NV engages in the development of medical solutions. It offers research and development services in the field of mental illness, neurological disorders, anesthesia, analgesia, gastrointestinal disorders, fungal infection, allergies and cancer. The firms products include Zytiga, Caelyx, Dacogen, Edurant, Fentanyl-Janssen, Intelence, Leustatin, , Pariet, and Reminyl. The company was founded in 1953 by Paul Janssen and is headquartered in Beerse, Belgium.

Kings' Holdings LLC Owns and operates educational institutions. The company holds and manages Schools and learning facilities. The company was founded in 2004 and it is headquartered in Dubai, United Arab Emirates.

InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands.

FABPulous BV develops a handheld disposable plasma separation device with embedded in vitro diagnostic test capability. It offers ultra rapid plasma preparation platform that can make a defined dilution of plasma from a small volume of whole blood in seconds and integrated lateral flow IVD platform. The company’s tests provide diagnosis and benefit to the patient, as well as the healthcare sector, the insurance industry, governments and society in general. FABPulous was founded in 2008 and is headquartered in Maastricht, the Netherlands.

Astellas Pharma SAS wholesales pharmaceutical products. The company was founded in 2005 and is headquartered in Levallois-Perret, France.

DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands.

NightBalance BV develops and markets sensor-devices for the treatment of sleep apnea. It offers sleep position trainer, a small and light aid which can be worn around the chest with an ergonomic band. The firm's a sleep position sensor which gradually and comfortably trains patients using vibrations to not sleep on their back. The company was founded by Eline van Beest and Thijs van Oorschot in 2009 and is headquartered in The Hague, the Netherlands.

Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands.

Mellon Medical BV manufactures and develops surgical suturing devices. The firm’s suturing device, the Switch, is designed for surgeons who perform the challenging operations and can easily be rotated in the hand because of its pencil-like shape. The company was founded in April 2013 by Mark Vrancken Peeters and is headquartered in Nijmegen, the Netherlands.

Nutrileads BV develops food ingredi?nts with a specific nutritional value. It identifies promising lead ingredients, develops sustainable and commercially viable production processes and initiates scientific and clinical programs to test the health effects. The company was founded in 2012 by Erik Dam and Ruud Albers and is headquartered in Wageningen, the Netherlands.

Waterman 40 Holding BV (Waterman 40 Holding) is an Independent Private Equity/Venture Capital firm founded in 2015. The firm is headquartered in Maarsbergen.

Neuroplast BV is a Dutch stem cell technology company that focuses on developing autologous cell products for the treatment of primarily inflammation-driven neurological disorders. Neuroplast is located in Brightlands Chemelot Campus in the Netherlands. The company's transformative treatment, Neuro-cellsò, is currently being tested for traumatic spinal cord injury (TSCI) and aims to reduce the irreversible impact of TSCI during the crucial first phase. The company was founded in August 2014 by physician De Munter and neurologist Erik Wolters, and current investors include Invest, Brightlands Venture Partners, and Liof NV. Johannes de Munter has been the CEO of the company since 2016.

Pan Cancer T is a company based in Rotterdam, Netherlands that was founded in 2020 by Reno Debets, Dora Hammerl. The Dutch company focuses on advancing next generation TCR T cell therapies for hard-to-treat solid tumors. The company's approach includes exploiting unique targets for T cells that are exclusively and robustly expressed by multiple solid cancers and developing technologies that enhance the durability of the T cells. The company has ongoing R & D programs to develop safe and effective adoptive T cell therapies for patients with triple negative breast cancer as well as cancers of the bladder, ovarium, colorectum, prostate, skin, esophagus, lung, or brain. Rachel Abbott has been the CEO of the company since 2023.

EsoBiotec SA is a Belgian company that provides research and development on natural sciences and engineering. The company is based in Charleroi, Belgium. The company was founded in 2020 by Jean-Pierre Latere. Jean-Pierre Latere has been the CEO since 2020.

Prothya Biosolutions Belgium BV is a Belgian company that was founded in 1997. The private company is based in Brussels, Belgium. The company manufactures plasma and pharmaceutical raw materials and operate as blood transfusion centers and organ banks.

FundaMental Pharma GmbH is a neuroscience company based in Heidelberg, Germany. The German company develops first-in-class small inhibitors for the treatment of a range of neurodegenerative diseases. The company's scientists have discovered an entirely new class of drugs that safely counteract glutamate excitotoxicity, a common cause of neurodegeneration. The company's current focus is on amyotrophic lateral sclerosis (ALS) and Huntington's disease, but the applicability of these molecules extends to a range of neurodegenerative disorders such as dementia and aging-related memory loss. FundaMental Pharma was founded in 2016 by Thomas Schulze, Hilmar Bading, and Daniela Mauceri, and Thomas Schulze has been the CEO since 2016.